EUCOPE

EUCOPE
Type	Association without lucrative purpose
Industry	Pharmaceutical Industry
Founded	November 2008
Headquarters	Brussels, Belgium
Website	http://www.eucope.org/en/

EUCOPE (www.eucope.org) was founded in 2008 in Brussels and promotes companies and associations active in research, development, production and distribution of pharmaceutical products and enhances their scientific, technical, economic and legal objectives.

Via the member associations (the German Pharmaceutical Industry Association (BPI), the Ethical Medicines Industry Group (EMIG) of the UK, the Swedish Associations SwedenBio and IML as well as BioDeutschland) EUCOPE represents more than 900 mid-sized innovative member companies, many of them SMEs. In addition, many innovative companies from Sweden, UK, France, Bulgaria, Italy, Greece, Germany, the Netherlands and Austria are represented on the Board of the association. EUCOPE membership includes innovative family owned companies such as Sigma-Tau, Ferring, B.Braun, Vianex or Bionorica as well as innovative companies active in the field of rare diseases such as Alexion, Celgene, Otsuka or Grifols (http://www.eucope.org/en/about-us/members/ / http://www.eucope.org/en/positions/).

Structure

President of the Association: Jan G. Smith, ABIGO Medial AB, Sweden.
Vice-President: Dr. Bernd Wegener, B.R.A.H.M.S AG, Germany.
Vice-President: Stefano Bonani, SEGIX ITALIA srl, Italy
Treasurer: Dr. Sigurd Pütter, Arzneimittel Pütter GmbH & Co. KG, Germany
Secretary General: Dr. Alexander Natz

Policy Objectives

EUCOPE is active in the above mentioned areas:

Transparent reimbursement and pricing decisions
Fast national marketing authorisation procedures
Incentives for incremental research
Public perception of pharmaceutical innovations by SMEs
Increased need for collaboration
Community patent and strong intellectual property rights
Recast of the clinical trials legislation
Informed patient as political objective
Effective promotion of R&D by tax incentives
Reduced VAT rates for pharmaceuticals
Prevention of late payment by public authorities
Pharmacovigilance
Transparency Directive
Orphan Drugs

External links

This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.